Natural Investments LLC Purchases New Position in McKesson Co. (NYSE:MCK)

Natural Investments LLC purchased a new stake in shares of McKesson Co. (NYSE:MCK - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 572 shares of the company's stock, valued at approximately $325,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MCK. Synergy Asset Management LLC bought a new stake in shares of McKesson in the 4th quarter valued at approximately $32,000. MidAtlantic Capital Management Inc. bought a new stake in shares of McKesson in the 3rd quarter valued at approximately $29,000. Crews Bank & Trust bought a new stake in shares of McKesson in the 4th quarter valued at approximately $33,000. RPg Family Wealth Advisory LLC bought a new stake in shares of McKesson in the 3rd quarter valued at approximately $31,000. Finally, Creative Capital Management Investments LLC bought a new stake in shares of McKesson in the 4th quarter valued at approximately $44,000. 85.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of McKesson stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $597.99, for a total transaction of $5,358,588.39. Following the completion of the sale, the chief executive officer now owns 60,664 shares of the company's stock, valued at approximately $36,276,465.36. The trade was a 12.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Leann B. Smith sold 579 shares of McKesson stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the sale, the executive vice president now directly owns 864 shares of the company's stock, valued at approximately $494,890.56. This represents a 40.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,689 shares of company stock worth $11,187,351 in the last ninety days. 0.11% of the stock is owned by insiders.

McKesson Trading Down 0.8 %

Shares of NYSE:MCK opened at $653.54 on Wednesday. McKesson Co. has a 12-month low of $464.42 and a 12-month high of $663.61. The business's fifty day simple moving average is $604.12 and its 200-day simple moving average is $568.96. The company has a market capitalization of $81.91 billion, a PE ratio of 29.92, a P/E/G ratio of 1.29 and a beta of 0.52.

Remove Ads

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Research analysts predict that McKesson Co. will post 32.77 EPS for the current year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $2.84 annualized dividend and a yield of 0.43%. McKesson's dividend payout ratio (DPR) is 13.00%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on MCK shares. Evercore ISI raised their price objective on McKesson from $650.00 to $675.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Morgan Stanley raised their price target on McKesson from $612.00 to $642.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 17th. Wells Fargo & Company raised their price target on McKesson from $535.00 to $641.00 and gave the stock an "equal weight" rating in a research note on Friday, December 13th. StockNews.com lowered McKesson from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Finally, Citigroup decreased their price target on McKesson from $713.00 to $677.00 and set a "buy" rating for the company in a research note on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, McKesson currently has an average rating of "Moderate Buy" and a consensus price target of $645.79.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.